8-K
filed November 9, 2022, 6:59 PM ET
ticker MXCT
CIK 0001287098
earnings
confidence high
sentiment negative
materiality 0.65
MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M
MAXCYTE, INC.
2022-Q3 EPS reported
-$0.18
revenue$31,837,900
- Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.
- Net loss widened to $6.4M from $2.7M; EBITDA loss $7.1M vs $2.4M loss a year ago.
- Cash and equivalents $232.9M; operating expenses rose to $17.0M from $11.6M on staffing and R&D.
- Reiterated FY2022 guidance: core revenue growth ~30%, SPL program revenue ~$4.0M.
- Cell therapy revenue $7.9M (+27%), drug discovery $2.0M (+4%); SPL revenue fell 62% to $0.8M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.7
MAXCYTE, INC. reported financial results for the nine months ended September 30, 2022.
- Period
- the nine months ended September 30, 2022
- Result
- reported results
Exact text from the filing
announcing its financial results for the quarter and nine months ended September 30, 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
MAXCYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $10.6 million, net income $6.4 million. Guidance reaffirmed.
- Period
- the third quarter ended September 30, 2022
- Revenue
- $10.6 million
- Net income
- $6.4 million
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
Total revenue of $10.6 million in the third quarter of 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.